Source: Clinics. Conference titles: Simpósio avanços em pesquisas médicas. Unidade: FM
Subjects: CAMUNDONGOS, NEOPLASIAS CUTÂNEAS (GENÉTICA), ANTINEOPLÁSICOS, RESUMOS (SIMPÓSIOS)
ABNT
COSTA, P. L. N. et al. Combined use of the bradykinin B1R antagonist R954 and the chemotherapeutic agent dacarbazine increased global survival of melanoma-bearing mice. Clinics. São Paulo: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 23 maio 2024. , 2007APA
Costa, P. L. N., Andrade, L. N. S., Nantel, F., Battistini, B., Sirois, P., & Chammas, R. (2007). Combined use of the bradykinin B1R antagonist R954 and the chemotherapeutic agent dacarbazine increased global survival of melanoma-bearing mice. Clinics. São Paulo: Faculdade de Medicina, Universidade de São Paulo.NLM
Costa PLN, Andrade LNS, Nantel F, Battistini B, Sirois P, Chammas R. Combined use of the bradykinin B1R antagonist R954 and the chemotherapeutic agent dacarbazine increased global survival of melanoma-bearing mice. Clinics. 2007 ; 62 S56.[citado 2024 maio 23 ]Vancouver
Costa PLN, Andrade LNS, Nantel F, Battistini B, Sirois P, Chammas R. Combined use of the bradykinin B1R antagonist R954 and the chemotherapeutic agent dacarbazine increased global survival of melanoma-bearing mice. Clinics. 2007 ; 62 S56.[citado 2024 maio 23 ]